Vertex Pharmaceuticals reported 10.8M in Interest Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Acadia Pharmaceuticals ACAD:US 580K 475K
Alnylam Pharmaceuticals ALNY:US 1.9M 887K
Arrowhead Research ARWR:US 1.24M 186K
Biogen BIIB:US 12.6M 9.7M
BioMarin Pharmaceutical BMRN:US 2.5M 685K
Bluebird Bio BLUE:US 174K 68K
Moderna Inc MRNA:US 40M 25M
Pfizer PFE:US 30M 16M
Puma Biotechnology PBYI:US 65K 52K
Sangamo BioSciences SGMO:US 2.64M 1.3M
Sarepta Therapeutics SRPT:US 2.41M 2.24M
Ultragenyx Pharmaceutical RARE:US 899K 405K
United Therapeutics UTHR:US 6.8M 2.5M
Vertex Pharmaceuticals VRTX:US 10.8M 9.2M